Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

Ibrutinib Plus Obinutuzumab Superior to Standard Chemoimmunotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia

Treatment with the regimen of ibrutinib plus obinutuzumab improved outcomes for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),...

For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy

Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...
WIB_icon

Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL

In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...

Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL

In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...

Weighing Conditioning Regimens for Patients With CML Undergoing Transplant

Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...

Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety

Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...

How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...

Demystifying Epigenetics in Hematology

In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

Next Steps After TKIs for Patient With Chronic-Phase CML?

Here’s how readers responded to a You Make the Call question about the next steps after TKIs for patient with chronic-phase chronic myeloid leukemia. Disclaimer:...

Next Steps After TKIs for Patient With Chronic-Phase CML?

This month, Michael Deininger, MD, PhD, discusses treatment for a patient with chronic-phase chronic myeloid leukemia (CML) whose BCR/ABL transcript levels are rising. And don't...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.